St Jude's Unify and Fortify CRM devices hit Japan
This article was originally published in Clinica
St Jude Medical's Fortify ST implantable cardioverter defibrillator (ICD) and Unify cardiac resynchronisation therapy defibrillator (CRT-D) have been approved and launched in Japan. The devices, which St Paul, Minnesota firm claims are the smallest of their type, feature advanced battery technology and circuitry that allow for a smaller device, with more energy capacity, faster charge times, and increased longevity. The energy capacity of a device is particularly important for patients who have an enlarged heart, low ejection fraction, advanced heart failure or a high defibrillation threshold. They also incorporate a monitoring algorithm and technology designed to reduce inappropriate and unnecessary shocks. Unify and Fortify gained US premarket approval (PMA) last May (www.clinica.co.uk, 14 May 2010).
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.